vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and UNITY BANCORP INC (UNTY). Click either name above to swap in a different company.
UNITY BANCORP INC is the larger business by last-quarter revenue ($35.3M vs $23.0M, roughly 1.5× Intellia Therapeutics, Inc.). UNITY BANCORP INC runs the higher net margin — 43.9% vs -416.2%, a 460.0% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 24.2%). UNITY BANCORP INC produced more free cash flow last quarter ($44.3M vs $-69.4M). Over the past eight quarters, UNITY BANCORP INC's revenue compounded faster (17.5% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
Unity Bancorp Inc is a New Jersey-headquartered financial holding company operating Unity Bank. It offers a full range of commercial and retail banking services including business loans, deposit products, mortgage services, and personal banking solutions, primarily serving small and medium-sized enterprises and individual consumers across local communities in New Jersey and eastern Pennsylvania.
NTLA vs UNTY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $35.3M |
| Net Profit | $-95.8M | $15.5M |
| Gross Margin | — | — |
| Operating Margin | -428.9% | 55.8% |
| Net Margin | -416.2% | 43.9% |
| Revenue YoY | 78.8% | 24.2% |
| Net Profit YoY | 25.7% | 34.5% |
| EPS (diluted) | $-0.81 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $35.3M | ||
| Q3 25 | $13.8M | $32.8M | ||
| Q2 25 | $14.2M | $34.4M | ||
| Q1 25 | $16.6M | $29.4M | ||
| Q4 24 | $12.9M | $28.4M | ||
| Q3 24 | $9.1M | $27.7M | ||
| Q2 24 | $7.0M | $25.5M | ||
| Q1 24 | $28.9M | $25.6M |
| Q4 25 | $-95.8M | $15.5M | ||
| Q3 25 | $-101.3M | $14.4M | ||
| Q2 25 | $-101.3M | $16.5M | ||
| Q1 25 | $-114.3M | $11.6M | ||
| Q4 24 | $-128.9M | $11.5M | ||
| Q3 24 | $-135.7M | $10.9M | ||
| Q2 24 | $-147.0M | $9.5M | ||
| Q1 24 | $-107.4M | $9.6M |
| Q4 25 | -428.9% | 55.8% | ||
| Q3 25 | -808.9% | 57.5% | ||
| Q2 25 | -772.2% | 62.6% | ||
| Q1 25 | -726.6% | 52.6% | ||
| Q4 24 | -1059.9% | 51.0% | ||
| Q3 24 | -1589.0% | 52.7% | ||
| Q2 24 | -1998.6% | 49.3% | ||
| Q1 24 | -394.0% | 50.0% |
| Q4 25 | -416.2% | 43.9% | ||
| Q3 25 | -735.2% | 43.8% | ||
| Q2 25 | -710.8% | 48.0% | ||
| Q1 25 | -687.6% | 39.5% | ||
| Q4 24 | -1001.2% | 40.5% | ||
| Q3 24 | -1489.5% | 39.4% | ||
| Q2 24 | -2112.6% | 37.1% | ||
| Q1 24 | -371.3% | 37.5% |
| Q4 25 | $-0.81 | $1.52 | ||
| Q3 25 | $-0.92 | $1.41 | ||
| Q2 25 | $-0.98 | $1.61 | ||
| Q1 25 | $-1.10 | $1.13 | ||
| Q4 24 | $-1.27 | $1.13 | ||
| Q3 24 | $-1.34 | $1.07 | ||
| Q2 24 | $-1.52 | $0.92 | ||
| Q1 24 | $-1.12 | $0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $671.4M | $345.6M |
| Total Assets | $842.1M | $3.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.9M | — | ||
| Q3 25 | $511.0M | — | ||
| Q2 25 | $459.7M | — | ||
| Q1 25 | $503.7M | — | ||
| Q4 24 | $601.5M | — | ||
| Q3 24 | $658.1M | — | ||
| Q2 24 | $691.1M | — | ||
| Q1 24 | $791.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $230.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $671.4M | $345.6M | ||
| Q3 25 | $748.4M | $334.0M | ||
| Q2 25 | $715.3M | $319.8M | ||
| Q1 25 | $779.9M | $306.1M | ||
| Q4 24 | $872.0M | $295.6M | ||
| Q3 24 | $962.6M | $284.3M | ||
| Q2 24 | $971.1M | $273.4M | ||
| Q1 24 | $1.0B | $266.8M |
| Q4 25 | $842.1M | $3.0B | ||
| Q3 25 | $925.3M | $2.9B | ||
| Q2 25 | $898.9M | $2.9B | ||
| Q1 25 | $986.2M | $2.8B | ||
| Q4 24 | $1.2B | $2.7B | ||
| Q3 24 | $1.2B | $2.6B | ||
| Q2 24 | $1.2B | $2.6B | ||
| Q1 24 | $1.3B | $2.6B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | $44.9M |
| Free Cash FlowOCF − Capex | $-69.4M | $44.3M |
| FCF MarginFCF / Revenue | -301.6% | 125.7% |
| Capex IntensityCapex / Revenue | 0.5% | 1.6% |
| Cash ConversionOCF / Net Profit | — | 2.90× |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | $81.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.3M | $44.9M | ||
| Q3 25 | $-76.9M | $45.5M | ||
| Q2 25 | $-99.6M | $-25.3M | ||
| Q1 25 | $-148.9M | $17.9M | ||
| Q4 24 | $-85.2M | $48.0M | ||
| Q3 24 | $-84.8M | $17.7M | ||
| Q2 24 | $-58.2M | $-8.4M | ||
| Q1 24 | $-120.7M | $15.8M |
| Q4 25 | $-69.4M | $44.3M | ||
| Q3 25 | $-76.9M | $45.3M | ||
| Q2 25 | $-99.9M | $-25.5M | ||
| Q1 25 | $-149.7M | $17.6M | ||
| Q4 24 | $-86.2M | $47.3M | ||
| Q3 24 | $-86.1M | $17.5M | ||
| Q2 24 | $-59.2M | $-8.6M | ||
| Q1 24 | $-123.2M | $15.7M |
| Q4 25 | -301.6% | 125.7% | ||
| Q3 25 | -558.2% | 138.1% | ||
| Q2 25 | -701.0% | -74.2% | ||
| Q1 25 | -900.1% | 59.9% | ||
| Q4 24 | -669.4% | 166.5% | ||
| Q3 24 | -945.2% | 63.3% | ||
| Q2 24 | -850.9% | -33.7% | ||
| Q1 24 | -425.7% | 61.4% |
| Q4 25 | 0.5% | 1.6% | ||
| Q3 25 | 0.2% | 0.7% | ||
| Q2 25 | 1.7% | 0.5% | ||
| Q1 25 | 4.4% | 1.0% | ||
| Q4 24 | 7.6% | 2.4% | ||
| Q3 24 | 14.0% | 0.5% | ||
| Q2 24 | 14.5% | 0.5% | ||
| Q1 24 | 8.7% | 0.3% |
| Q4 25 | — | 2.90× | ||
| Q3 25 | — | 3.16× | ||
| Q2 25 | — | -1.54× | ||
| Q1 25 | — | 1.54× | ||
| Q4 24 | — | 4.17× | ||
| Q3 24 | — | 1.62× | ||
| Q2 24 | — | -0.89× | ||
| Q1 24 | — | 1.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
UNTY
Segment breakdown not available.
